Acura OTC Stock Analysis

ACUR
 Stock
  

USD 0.01  0.00  0.00%   

The big decline in price over the last few months for Acura Pharma Cmn could raise concerns from retail investors as the firm is trading at a share price of 0.01 on slow start in volume. The company executives failed to add value to investors and position the firm supply of money to exploit market volatility in August. However, diversifying your holdings with Acura Pharma Cmn or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 20.27. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Acura Pharma partners.
Please continue to Trending Equities.
  
The Acura Pharma otc stock analysis report makes it easy to digest most publicly released information about Acura Pharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Acura OTC Stock analysis module also helps to analyze the Acura Pharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Acura OTC Stock Analysis Notes

About 19.0% of the company shares are held by company insiders. The company has Price/Earnings (P/E) ratio of 125.0. Acura Pharma Cmn recorded a loss per share of 0.04. The entity had not issued any dividends in recent years. The firm had 1:5 split on the 28th of August 2015. Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 12 people.The quote for Acura Pharma Cmn is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. For more info on Acura Pharma Cmn please contact Robert Jones at 847 705 7709 or go to https://www.acurapharm.com.

Acura Pharma Cmn Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more otcs at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Acura Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Acura Pharma Cmn or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Acura Pharma Cmn generated a negative expected return over the last 90 days
Acura Pharma Cmn has high historical volatility and very poor performance
Acura Pharma Cmn has some characteristics of a very speculative penny stock
Acura Pharma Cmn has a very high chance of going through financial distress in the upcoming years
The company currently holds 324 K in liabilities with Debt to Equity (D/E) ratio of 2.4, implying the company greatly relies on financing operations through barrowing. Acura Pharma Cmn has a current ratio of 0.84, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Acura Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Acura Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acura Pharma Cmn sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acura to invest in growth at high rates of return. When we think about Acura Pharma's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 2.25 M. Net Loss for the year was (1.15 M) with profit before overhead, payroll, taxes, and interest of 1.79 M.
Acura Pharma Cmn currently holds about 89 K in cash with (396 K) of positive cash flow from operations.
Roughly 19.0% of Acura Pharma shares are held by company insiders

Acura Pharma Cmn Upcoming and Recent Events

Earnings reports are used by Acura Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Acura Pharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report30th of March 2022
Next Fiscal Quarter End31st of December 2021

Acura Pharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Acura Pharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Acura Pharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Acura Pharma Cmn specific information freely available to individual and institutional investors to make a timely investment decision.
26th of August 2022
Financial Statements and Exhibits. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement
View
28th of July 2022
Other Events
View
19th of July 2022
Financial Statements and Exhibits. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement
View
14th of July 2022
Other Events
View
11th of July 2022
Financial Statements and Exhibits. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement
View
13th of June 2022
Financial Statements and Exhibits. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement
View
23rd of May 2022
Financial Statements and Exhibits. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement
View
19th of May 2022
Other Events
View

Acura Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Acura Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Acura Pharma Cmn backward and forwards among themselves. Acura Pharma's institutional investor refers to the entity that pools money to purchase Acura Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Captrust Financial AdvisorsCommon Shares2450.0
Lenox Wealth Advisors LlcCommon Shares7800.0
Captrust Financial AdvisorsCommon Shares2450.0
Lenox Wealth Advisors LlcCommon Shares7800.0
Captrust Financial AdvisorsCommon Shares2450.0
Lenox Wealth Advisors LlcCommon Shares7800.0
Lenox Wealth Advisors LlcCommon Shares7801000
Note, although Acura Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Acura Market Capitalization

The company currently falls under 'Nano-Cap' category with current market capitalization of 650.89 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Acura Pharma's market, we take the total number of its shares issued and multiply it by Acura Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Acura Profitablity

Acura Pharma's profitability indicators refer to fundamental financial ratios that showcase Acura Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Acura Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Acura Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Acura Pharma's profitability requires more research than a typical breakdown of Acura Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (51.27) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (49.35) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.49.

Management Efficiency

The entity has return on total asset (ROA) of (38.42) % which means that it has lost $38.42 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.85 %, meaning that it created $0.85 on every $100 dollars invested by stockholders. Acura Pharma management efficiency ratios could be used to measure how well acura pharma cmn manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 25th of September, Acura Pharma shows the mean deviation of 8.57, and Risk Adjusted Performance of (0.14). Acura Pharma Cmn technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to break down and analyze data for nineteen technical drivers for Acura Pharma Cmn, which can be compared to its rivals. Please confirm Acura Pharma Cmn variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Acura Pharma Cmn is priced correctly, providing market reflects its regular price of 0.01 per share. As Acura Pharma Cmn appears to be a penny stock we also recommend to validate its total risk alpha numbers.

Acura Pharma Cmn Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Mid-point over period is an average of Acura Pharma Cmn highest and lowest values attained during the given period.
.

Acura Pharma Cmn Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Acura Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Acura Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Acura Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Acura Pharma Predictive Daily Indicators

Acura Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Acura Pharma otc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Acura Pharma Forecast Models

Acura Pharma time-series forecasting models is one of many Acura Pharma's otc stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Acura Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Acura OTC Stock Analysis

OTC Stock analysis is the technique used by a trader or investor to examine and evaluate how Acura Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Acura shares will generate the highest return on investment. We also built our otc analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual OTC such as Acura Pharma. By using and applying Acura OTC Stock analysis, traders can create a robust methodology for identifying Acura entry and exit points for their positions.
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 12 people.

Current Acura Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Acura analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Acura analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
6.0Strong Buy1Odds
Acura Pharma Cmn current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Acura analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Acura stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Acura Pharma Cmn, talking to its executives and customers, or listening to Acura conference calls.
Acura Analyst Advice Details

Acura OTC Stock Analysis Indicators

Acura Pharma Cmn otc stock analysis indicators help investors evaluate how Acura Pharma otc stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Acura Pharma shares will generate the highest return on investment. By understating and applying Acura Pharma otc stock analysis, traders can identify Acura Pharma position entry and exit signals to maximize returns.
Quick Ratio0.64
Fifty Two Week Low0.0100
Revenue Growth-34.10%
Shares Short Prior Month76k
Average Daily Volume Last 10 Day120
Average Daily Volume In Three Month9.92k
Shares Percent Shares Out0.76%
Gross Margins28.28%
Short Percent Of Float1.20%
Forward Price Earnings0.03
Float Shares9.45M
Fifty Two Week High0.6000
Enterprise Value To Ebitda-7.15
Fifty Day Average0.1160
Two Hundred Day Average0.3871
Enterprise Value To Revenue3.29
Please continue to Trending Equities. You can also try Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for analysis

When running Acura Pharma Cmn price analysis, check to measure Acura Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acura Pharma is operating at the current time. Most of Acura Pharma's value examination focuses on studying past and present price action to predict the probability of Acura Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Acura Pharma's price. Additionally, you may evaluate how the addition of Acura Pharma to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Is Acura Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acura Pharma. If investors know Acura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acura Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Acura Pharma Cmn is measured differently than its book value, which is the value of Acura that is recorded on the company's balance sheet. Investors also form their own opinion of Acura Pharma's value that differs from its market value or its book value, called intrinsic value, which is Acura Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acura Pharma's market value can be influenced by many factors that don't directly affect Acura Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acura Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Acura Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acura Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.